There have been numerous studies of the effects of neuroleptic discontinuation in young schizophrenic patients. Yet little information is available regarding the same in older schizophrenic patients. Longitudinal studies of the course of schizophrenia have found that over time many patients fully recover or significantly improve. At the same time, the risk of persistent tardive dyskinesia (TD) is high among older patients maintained on neuroleptics. Hence a study of the effects of neuroleptic discontinuation on relapse aid on TD in the older subject population is warranted. We will study 160 chronic schizophrenic patients over age 45 (mean age 60 to 65 years), recruited over the first 4-year period. Baseline psychiatric assessments will be done after a patient is stabilized on the present neuroleptic dose for at least 1 month. These will include: Brief Psychiatric Rating Scale (BPRS); Scales for Assessment of Positive Symptoms (SAPS); Scale for Assessment of Negative Symptoms (SANS); Positive and Negative Syndrome Scale (PANSS); Schedule for the Deficit Syndrome (SDS); Dementia Rating Scale (DRS); Abnormal Involuntary Movement Scale (AIMS); Hamilton Rating Scale for Depression (HAM-D); Cumulative Illness Rating Scale - Geriatrics (CIRS-G); and Brief Symptom Inventory (BSI). The neuroleptic medication will be reduced by 25% every other week and discontinued at the end of the sixth week. We expect 100 patients to complete neuroleptic taper. Most rating scales will be repeated biweekly during the taper and for 4 weeks afterwards, and monthly thereafter. All the ratings will be done by """"""""blind"""""""" raters. Patients will be maintained off neuroleptics unless and until they relapse. We hypothesize that: (l) Schizophrenic patients who are older, those who have later onset of illness, and those of the paranoid or residual type will be more likely to complete neuroleptic discontinuation; (2) The risk of relapse will be negatively associated with current age and age of onset of schizophrenia and positively associated with severity of positive symptoms, degree of cognitive impairment and presence of TD at baseline; (3) Among schizophrenic patients who complete neuroleptic taper, there will be a positive correlation between change in severity of TD and change in negative symptoms; and (4) Remission of TD after neuroleptic discontinuation will be associated with lower AIMS score at baseline, younger age and lower negative and affective symptom scores at baseline. We will use survival analysis and other appropriate statistical analyses for testing the hypotheses. We believe that the results of our study will have considerable clinical and theoretical implications.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29MH051459-02
Application #
2250704
Study Section
Mental Disorders of Aging Review Committee (MDA)
Project Start
1994-05-01
Project End
1999-04-30
Budget Start
1995-05-01
Budget End
1996-04-30
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Psychiatry
Type
Schools of Medicine
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Wetherell, Julie Loebach; Palmer, Barton W; Thorp, Steven R et al. (2003) Anxiety symptoms and quality of life in middle-aged and older outpatients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 64:1476-82
Dolder, Christian R; Lacro, Jonathan P; Leckband, Susan et al. (2003) Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol 23:389-99
Kindermann, Sandra S; Dolder, Christian R; Bailey, Anne et al. (2002) Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience. Drugs Aging 19:257-76
Lindamer, L A; Buse, D C; Lohr, J B et al. (2001) Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? Biol Psychiatry 49:47-51
Lindamer, L A; Lohr, J B; Caligiuri, M P et al. (2001) Relationship of gender and age at onset of schizophrenia to severity of dyskinesia. J Neuropsychiatry Clin Neurosci 13:399-402
Jeste, D V; Unutzer, J (2001) Improving the delivery of care to the seriously mentally ill. Med Care 39:907-9
Dunn, L B; Lindamer, L A; Palmer, B W et al. (2001) Enhancing comprehension of consent for research in older patients with psychosis: a randomized study of a novel consent procedure. Am J Psychiatry 158:1911-3
Dunn, L B; Jeste, D V (2001) Enhancing informed consent for research and treatment. Neuropsychopharmacology 24:595-607
Lindamer, L A; Lohr, J B; Harris, M J et al. (1999) Gender-related clinical differences in older patients with schizophrenia. J Clin Psychiatry 60:61-7;quiz 68-9
Lindamer, L A; Lohr, J B; Harris, M J et al. (1997) Gender, estrogen, and schizophrenia. Psychopharmacol Bull 33:221-8